Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET.

The session will be webcast live and archived for 90 days under the Investors tab at the company website.

News Market Reaction – ABOS

+3.64%

1 alert

+3.64% Session close to close

$185.62M Market Cap

1.39K Volume

In the May 8 session, ABOS gained 3.64%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights ABOS management’s participation in a Bank of America healthcare confere...

Analysis

This announcement highlights ABOS management’s participation in a Bank of America healthcare conference, adding another venue for investor outreach. With shares trading above the $2.09 200-day MA but still below the 52-week high, context from recent earnings, financing, and regulatory filings remains important. Investors may watch for any new commentary from the fireside chat and for subsequent clinical or financial disclosures to gauge the company’s evolving outlook.

Key Figures

Conference date: May 14, 2026 Session time PT: 8:55 a.m. PT Session time ET: 11:55 a.m. ET +1 more

4 metrics

Conference date May 14, 2026 Bank of America Securities 2026 Health Care Conference fireside chat

Session time PT 8:55 a.m. PT Scheduled start time for fireside chat

Session time ET 11:55 a.m. ET Scheduled start time for fireside chat

Webcast archive duration 90 days Replay availability under Investors tab on company website

Historical Context

5 past events · Latest: May 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 05	Earnings call scheduled	Neutral	+2.0%	Announcement of timing for Q1 2026 financial results and webcast.
Mar 26	Full-year earnings	Negative	-3.0%	Reported higher 2025 net loss and increased R&D spending with going concern note.
Mar 19	Earnings date set	Neutral	-8.6%	Set date and logistics for Q4 and year-end 2025 earnings call.
Mar 17	Scientific data update	Positive	-7.5%	Presented new preclinical and biomarker data on enhanced brain delivery and antibodies.
Mar 16	Private placement	Neutral	+1.5%	Announced $35.75M private placement at $3.30 per share to fund EBD program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ABOS has seen mixed reactions: earnings and financing updates often align with price direction, while positive scientific data previously coincided with a price decline.

Recent Company History

Over recent months, ABOS has alternated between clinical updates, financing, and routine earnings communications. A $35.75M private placement in mid-March 2026 funded its Enhanced Brain Delivery program, followed by full-year 2025 results outlining higher R&D spend and net loss. Scientific data at AD/PD 2026 was followed by a share price drop. The current conference-participation news fits the pattern of ongoing investor outreach alongside capital-raising and clinical milestones.

Key Terms

amyloid beta oligomers, alzheimer’s disease

2 terms

amyloid beta oligomers medical

"developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment"

Small, soluble clumps of a brain protein called amyloid beta that can interfere with nerve cell function and are suspected to drive memory loss in neurodegenerative disease. Investors watch them because drugs that reduce or neutralize these oligomers are a major focus of research, and convincing evidence that a treatment affects them can sway clinical trial success, regulatory decisions and a company’s valuation — like finding the right lock-and-key to stop engine damage.

alzheimer’s disease medical

"amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management"

A progressive brain disorder that gradually erodes memory, thinking and the ability to perform everyday tasks, similar to a computer slowly losing files and processing speed. It matters to investors because its large and growing patient population drives demand for treatments, long-term care, diagnostics and related services, making clinical trial results, regulatory decisions and patent exclusivity major value drivers for healthcare and biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m. PT/11:55 a.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE^® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. 

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
ICR Healthcare 
AcumenPR@icrhealthcare.com  

FAQ

When will Acumen Pharmaceuticals (ABOS) present at the Bank of America Securities 2026 Health Care Conference?

Acumen will present on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET. According to the company, the appearance is a fireside chat with management and is scheduled for that specific date and time.

How can investors watch the ABOS fireside chat on May 14, 2026?

Investors can watch the fireside chat via a live webcast on Acumen's investor website. According to the company, the webcast is available under the Investors tab at www.acumenpharm.com and will be archived for 90 days.

Will the Acumen Pharmaceuticals (ABOS) webcast be available after the live presentation?

Yes, the webcast will be archived for 90 days after the live presentation. According to the company, the archived video will remain accessible under the Investors tab on its website for three months.

What will Acumen Pharmaceuticals (ABOS) management discuss at the conference fireside chat?

Management will participate in a fireside chat at the health care conference on May 14, 2026. According to the company, the discussion will be led by company management; no additional agenda details were provided.

Where on the Acumen Pharmaceuticals website can I find the live webcast for the ABOS presentation?

The live webcast is posted under the Investors tab at www.acumenpharm.com. According to the company, viewers should access the Investors section to join the May 14, 2026 webcast and find the 90-day archive.